Phase III trial findings support the use of a liposome-encapsulated formulation of cytarabine and daunorubicin in older patients with a new diagnosis of high-risk secondary acute myeloid leukemia.

Each vial of the liposomal agent contains daunorubicin 44 mg and cytarabine 100 mg, and dosing should be calculated on the basis of the daunorubicin component, with a recommended dose of 44 mg/m 2 over a 90-minute infusion on days 1, 3, and 5 of the induction cycle.

Phase III trial findings support the use of a liposome-encapsulated formulation of cytarabine and daunorubicin in older patients with a new diagnosis of high-risk secondary acute myeloid leukemia.

The antibody–drug conjugate may now be given to newly diagnosed patients alongside daunorubicin and cytarabine chemotherapy, following results of the ALFA-0701 phase III trial of patients aged 50–70 years.

US researchers have detailed the pathophysiology, clinical presentation, and management of breast implant-associated anaplastic large cell lymphoma in a move to educate healthcare professionals dealing with this rare but increasingly common diagnosis.

The drug is intended for adult patients with a new diagnosis of FLT3 mutation-positive acute myeloid leukemia, to be given alongside standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy.

All participants in the CALGB 10603 (RATIFY) trial, conducted at 225 sites in 17 countries, received standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine).

Midostaurin should be used alongside standard cytarabine and daunorubicin induction therapy and cytarabine consolidation.